Can Pfizer Break Higher?

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

With shares of Pfizer (NYSE:PFE) trading around $29, is PFE an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let’s analyze the stock with the relevant sections of our CHEAT SHEET investing framework:

T = Trends for a Stock’s Movement

Pfizer is a biopharmaceutical company that discovers, develops, manufactures, and sells medicines for people and animals worldwide. The company manages its operations through five segments: Primary Care, Specialty Care and Oncology, Established Products and Emerging Markets, Animal Health and Consumer Healthcare, and Nutrition. Pfizer’s main products are human and animal biologic and small molecule medicines, as well as vaccines, nutritional products, consumer healthcare products, and products for the prevention and treatment of diseases in livestock and companion animals.

Patients who prefer brand-name cholesterol drug Lipitor to an inexpensive generic version will find it more affordable, thanks to a new discount offer from drugmaker Pfizer. They’ll be able to get Lipitor, the highest selling prescription medicine in history, for $30 or less per month — not much more than a generic — under Pfizer’s Lipitor Choice program. Patients who get a discount card at www.lipitor.com can receive a month’s supply for $30 if they have no insurance, are covered under Medicare or Affordable Care Act exchange plans, or have commercial insurance with a copayment of more than $130. If they have commercial insurance with a co-pay of $130 or less, it will cost them $4. Pfizer will pay the pharmacy any difference. The program is New York-based Pfizer’s latest effort to hang onto revenue from Lipitor, which generated nearly $13 billion in annual sales at its 2006 peak. Its patent expired in November 2011 in the U.S. and soon after in other major markets, allowing cheap copycat versions to flood pharmacies. “We are very keen to see how patients and physicians respond,” Sean Rapson, head of innovation for Pfizer’s established products business, told The Associated Press. “If there’s great interest, we would consider trying it with (our) other medicines.”

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business